KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Emergent BioSolutions (EBS) over the last 15 years, with Sep 2025 value amounting to -$400,000.

  • Emergent BioSolutions' Gains from Investment Securities was N/A to -$400,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year change of. This contributed to the annual value of -$6.5 million for FY2024, which is 180.25% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Gains from Investment Securities is -$400,000, which was up 81.82% from -$2.2 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Gains from Investment Securities registered a high of $18.9 million during Q4 2022, and its lowest value of -$2.6 million during Q4 2024.
  • In the last 3 years, Emergent BioSolutions' Gains from Investment Securities had a median value of $250,000 in 2023 and averaged $1.4 million.
  • In the last 5 years, Emergent BioSolutions' Gains from Investment Securities skyrocketed by 6,200.00% in 2022 and then crashed by 2,300.00% in 2025.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Gains from Investment Securities stood at $300,000 in 2021, then skyrocketed by 6,200.00% to $18.9 million in 2022, then slumped by 83.60% to $3.1 million in 2023, then plummeted by 183.87% to -$2.6 million in 2024, then crashed by 2,300.00% to -$400,000 in 2025.
  • Its Gains from Investment Securities stands at -$400,000 for Q3 2025, versus -$2.2 million for Q2 2025 and $11.3 million for Q1 2025.